What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Group ACYW135 Meningococcal Polysaccharide Vaccine market?

Key drivers include rising awareness, government initiatives, and advancements in vaccine technology.

What are the challenges facing the Group ACYW135 Meningococcal Polysaccharide Vaccine market?

Challenges include high development costs, stringent regulations, and vaccine hesitancy.

Who are the top companies in the Group ACYW135 Meningococcal Polysaccharide Vaccine market?

Top companies include Pfizer, Sanofi, and GlaxoSmithKline, which dominate the market with their vaccine products.

What are the future opportunities in the Group ACYW135 Meningococcal Polysaccharide Vaccine market?

Future opportunities include emerging markets, innovative vaccine technologies, and increasing collaborations.

What is the regulatory landscape for the Group ACYW135 Meningococcal Polysaccharide Vaccine market?

The regulatory landscape is stringent, with FDA and WHO guidelines governing vaccine development and approval.

Group ACYW135 Meningococcal Polysaccharide Vaccine Growth Trends & Strategic Outlook 2033

Group ACYW135 Meningococcal Polysaccharide Vaccine by Application (Hospital, Clinic), by Types (Class I Vaccines, Class II Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Group ACYW135 Meningococcal Polysaccharide Vaccine Market Size | CAGR 8.2 Forecast 2033

Group ACYW135 Meningococcal Polysaccharide Vaccine Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Group ACYW135 Meningococcal Polysaccharide Vaccine Market Overview

The Group ACYW135 Meningococcal Polysaccharide Vaccine market is a crucial segment of the global vaccine industry, playing a vital role in preventing meningococcal diseases. As the vaccine market continues to evolve, the Group ACYW135 Meningococcal Polysaccharide Vaccine market size is estimated to be approximately $1.4 billion in 2025. The growth outlook for this market is promising, with a projected market forecast of $2.5 billion by 2033, driven by increasing demand for effective vaccines and industry expansion. The scope of this market encompasses various synonyms, including meningococcal conjugate vaccines and polysaccharide vaccines.

Loading chart…

The Group ACYW135 Meningococcal Polysaccharide Vaccine market is expected to grow at a CAGR of 7-8% during the forecast period of 2026-2033, driven by macro drivers such as increasing awareness about meningococcal diseases, advancements in vaccine technology, and rising demand from emerging economies. Key forces shaping the industry include technology shifts towards conjugate vaccines, regulations supporting vaccine development, and competitive intensity among market players. The largest region for this market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and government initiatives to improve vaccination coverage. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.94 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi-Pasteur; Walvax Biotechnology; Chengdu Kanghua Biological Products Co.,Ltd; Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd; Zhejiang Tianyuan Biopharmaceutical Co.,Ltd; Beijing Institute of Biological Products Co.,Ltd; CanSino Biologics AG; Yuxi Watson Biotechnology Co.,Ltd; Hualan Biovaccine Co.,Ltd; Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Group ACYW135 Meningococcal Polysaccharide Vaccine market is poised for significant growth, driven by increasing demand for effective meningococcal disease prevention solutions. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

Advances in vaccine manufacturing technologies have improved the Group ACYW135 Meningococcal Polysaccharide Vaccine market size by increasing production efficiency and reducing costs, making vaccines more accessible to a broader population.

Government initiatives and immunization programs have contributed to the growth forecast of the Group ACYW135 Meningococcal Polysaccharide Vaccine market, with many countries implementing vaccination campaigns to prevent meningococcal disease outbreaks.

Restraints2 items

Stringent regulatory requirements and complex approval processes can hinder the growth forecast of the Group ACYW135 Meningococcal Polysaccharide Vaccine market, delaying the introduction of new vaccines and limiting their availability.

Vaccine hesitancy and public misconceptions about vaccine safety and efficacy can negatively impact the Group ACYW135 Meningococcal Polysaccharide Vaccine market size, reducing demand and slowing market growth.

Opportunities2 items

Emerging markets in developing countries present significant opportunities for the Group ACYW135 Meningococcal Polysaccharide Vaccine market, with growing demand for vaccines and increasing government investments in healthcare infrastructure.

The development of novel vaccine technologies, such as conjugate vaccines, can expand the Group ACYW135 Meningococcal Polysaccharide Vaccine market size by offering improved protection against meningococcal disease and enhancing vaccine efficacy.

Challenges2 items

Intensifying competition in the Group ACYW135 Meningococcal Polysaccharide Vaccine market can lead to pricing pressures and reduced profit margins, making it challenging for manufacturers to sustain their market position.

Supply chain disruptions and logistics challenges can impact the growth forecast of the Group ACYW135 Meningococcal Polysaccharide Vaccine market, affecting vaccine distribution and availability, particularly in remote or resource-constrained areas.

Market Segmentation

Loading chart…

The Application segment of the Group ACYW135 Meningococcal Polysaccharide Vaccine market refers to the various uses of the vaccine, including public health campaigns, travel medicine, and military medicine. This segment contributes to the overall market size by accounting for the different ways in which the vaccine is utilized to prevent meningococcal disease. Understanding the application segment is crucial for market players to develop targeted strategies and capitalize on emerging opportunities, ultimately informing the Group ACYW135 Meningococcal Polysaccharide Vaccine segmentation.

The Types segment of the Group ACYW135 Meningococcal Polysaccharide Vaccine market encompasses various subtypes, including [object Object] and [object Object]. This segment is critical in determining the overall market size, as different types of vaccines may have varying levels of demand, production costs, and market penetration. By analyzing the types segment, market players can identify areas of growth, optimize their product portfolios, and develop effective marketing strategies to capture a larger share of the market, which is essential for market taxonomy.

Group ACYW135 Meningococcal Polysaccharide Vaccine Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Class I Vaccines

Class II Vaccines

Regional Insights

Loading chart…

The Group ACYW135 Meningococcal Polysaccharide Vaccine market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of vaccines, investments in healthcare infrastructure, and a growing ecosystem maturity. Key drivers for North America include policies supporting vaccine development, high demographics awareness, and established infrastructure.

In Europe, key drivers include regulatory frameworks supporting vaccine distribution, public-private partnerships for vaccine development, and a mature healthcare ecosystem. Latin America is expected to be driven by government initiatives to improve vaccine access, demographic trends, and increasing healthcare investments. The Middle East & Africa region will be driven by international collaborations for vaccine distribution, infrastructure development, and a growing awareness of vaccine importance. These regional forecast trends are expected to shape the Group ACYW135 Meningococcal Polysaccharide Vaccine market.

Competitive Landscape

The Group ACYW135 Meningococcal Polysaccharide Vaccine market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. The market's competitive landscape is shaped by key levers including regulatory approvals, certifications, and partnerships. As a result, the Group ACYW135 Meningococcal Polysaccharide Vaccine competitive landscape is characterized by a high degree of competition, with companies seeking to differentiate themselves through various strategies.

Companies in this market employ various strategies to stay competitive, including mergers and acquisitions, partnerships, product launches, and research and development. However, they also face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies focus on factors like technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies to navigate this complex market:

Sanofi-Pasteur: regional expansion

Walvax Biotechnology: innovation pipeline

Chengdu Kanghua: local manufacturing

Beijing Zhifei: vertical integration

Zhejiang Tianyuan: premium pricing

Beijing Institute: OEM tie-ups

Key Group ACYW135 Meningococcal Polysaccharide Vaccine Companies10 items

Sanofi-Pasteur

Walvax Biotechnology

Chengdu Kanghua Biological Products Co.,Ltd

Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd

Zhejiang Tianyuan Biopharmaceutical Co.,Ltd

Beijing Institute of Biological Products Co.,Ltd

CanSino Biologics AG

Yuxi Watson Biotechnology Co.,Ltd

Hualan Biovaccine Co.,Ltd

Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd

Market Ecosystem

The Group ACYW135 Meningococcal Polysaccharide Vaccine ecosystem spans across upstream, midstream, and downstream activities, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of vaccines, with various participants contributing to the ecosystem's overall functionality. Understanding the Group ACYW135 Meningococcal Polysaccharide Vaccine ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — providing vaccine components

OEMs / manufacturers — producing vaccines

Technology providers — developing vaccine technologies

Distributors / channel partners — delivering vaccines to end users

Regulators/standards bodies — overseeing vaccine safety and efficacy

Service providers / after-sales — offering post-vaccination support

End users / buyers — administering vaccines to patients

In the Group ACYW135 Meningococcal Polysaccharide Vaccine ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as raw material availability, and standards compliance. Switching costs and partnerships between participants can also impact the ecosystem's dynamics. Furthermore, regional differences in vaccine demand, distribution channels, and regulatory frameworks can lead to variations in the ecosystem's structure and functioning across different regions.

Recent Industry Insights

The Group ACYW135 Meningococcal Polysaccharide Vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have led to the advancement of vaccine technologies. Notably, there have been several product launches and funding rounds that have further accelerated growth in the industry. Regulatory changes have also played a crucial role in shaping the industry, with authorities implementing stricter guidelines to ensure vaccine safety and efficacy.

Moreover, the industry has seen a shift in consumer trends, with increased awareness about the importance of vaccination against meningococcal diseases. This shift has driven demand for effective and safe vaccines, prompting companies to invest in research and development. As a result, the Group ACYW135 Meningococcal Polysaccharide Vaccine market is expected to experience continued growth, driven by these recent developments and advancements.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Group ACYW135 Meningococcal Polysaccharide Vaccine market. The market attractiveness is moderate, driven by increasing demand for preventive measures against meningococcal diseases. The competitive intensity is high, with multiple players operating in the market. The long-term outlook for the Group ACYW135 Meningococcal Polysaccharide Vaccine market outlook is positive, with growing awareness and government initiatives expected to drive growth.

The innovation landscape is characterized by ongoing research and development of novel vaccine candidates. The demand-supply balance is expected to be stable, with manufacturers increasing production to meet growing demand. However, key risk factors include regulatory changes, supply chain disruptions, and intense competition, which may impact market dynamics. Overall, the Group ACYW135 Meningococcal Polysaccharide Vaccine market is expected to experience steady growth, driven by increasing demand and advancements in vaccine technology.

11 items

1. Executive Summary

2. Group ACYW135 Meningococcal Polysaccharide Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Class I Vaccines

6.2.2. Class II Vaccines

6.3. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Competition by Key Manufacturers

8.1. Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Group ACYW135 Meningococcal Polysaccharide Vaccine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi-Pasteur

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Walvax Biotechnology

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chengdu Kanghua Biological Products Co.,Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Zhejiang Tianyuan Biopharmaceutical Co.,Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beijing Institute of Biological Products Co.,Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CanSino Biologics AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Yuxi Watson Biotechnology Co.,Ltd

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hualan Biovaccine Co.,Ltd

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market

Figure 4: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Drivers

Figure 5: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Challenges

Figure 6: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Trends

Figure 7: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Opportunity

Figure 8: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Restraint

Figure 9: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Figure 15: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Figure 23: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Table 10: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi-Pasteur Basic Information And Sales Area

Table 31: Sanofi-Pasteur. Products Portfolio

Table 32: Walvax Biotechnology Basic Information And Sales Area

Table 33: Walvax Biotechnology. Products Portfolio

Table 34: Chengdu Kanghua Biological Products Co.,Ltd Basic Information And Sales Area

Table 35: Chengdu Kanghua Biological Products Co.,Ltd. Products Portfolio

Table 36: Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd Basic Information And Sales Area

Table 37: Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd. Products Portfolio

Table 38: Zhejiang Tianyuan Biopharmaceutical Co.,Ltd Basic Information And Sales Area

Table 39: Zhejiang Tianyuan Biopharmaceutical Co.,Ltd. Products Portfolio

Table 40: Beijing Institute of Biological Products Co.,Ltd Basic Information And Sales Area

Table 41: Beijing Institute of Biological Products Co.,Ltd. Products Portfolio

Table 42: CanSino Biologics AG Basic Information And Sales Area

Table 43: CanSino Biologics AG. Products Portfolio

Table 44: Yuxi Watson Biotechnology Co.,Ltd Basic Information And Sales Area

Table 45: Yuxi Watson Biotechnology Co.,Ltd. Products Portfolio

Table 46: Hualan Biovaccine Co.,Ltd Basic Information And Sales Area

Table 47: Hualan Biovaccine Co.,Ltd. Products Portfolio

Table 48: Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd Basic Information And Sales Area

Table 49: Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Value (USD Million) By Region

Table 55: Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Group ACYW135 Meningococcal Polysaccharide Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.94 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi-Pasteur; Walvax Biotechnology; Chengdu Kanghua Biological Products Co.,Ltd; Beijing Zhifei Luzhu Biopharmaceutical Co.,Ltd; Zhejiang Tianyuan Biopharmaceutical Co.,Ltd; Beijing Institute of Biological Products Co.,Ltd; CanSino Biologics AG; Yuxi Watson Biotechnology Co.,Ltd; Hualan Biovaccine Co.,Ltd; Aimei Weixin Biopharmaceutical (Zhejiang) Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options